BioSpace News Archive

Bryn Pharma, LLC announced today that three abstracts will be presented during the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI).

BioIVT announced it has increased its capacity to deliver readily-available fresh, standard and mobilized, human leukopaks.

ReNAgade Therapeutics today announced that Amit D. Munshi, Chief Executive Officer, will virtually present at the Evercore ISI 2024 Emerging Biotech Conference on Thursday, February 29, 2024, at 9:35 a.m. ET.

CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).

Propanc Biopharma, Inc. today announced that members of the management will host a corporate update call on March 28, 2024, at 2:00 p.m., EST, to dive into the recent corporate updates and exciting positive results produced from a compassionate use study leveraging Propanc’s proenzyme therapy.

Kineta, Inc. announced today that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts.

Coya Therapeutics, Inc. announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, will present data on its novel oxidative stress biomarker candidate from a large cohort of Amyotrophic Latera Sclerosis (ALS) patients at the upcoming Society of Neuroimmune Pharmacology Conference being held on March 10-13, 2024 in Charleston, SC.

Ashvattha Therapeutics today announced that the first patient has been enrolled in its expanded Phase 1/2 study of 18F-OP-801, a hydroxyl dendrimer (HD) imaging agent.

ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA).

Avenue Therapeutics, Inc. today announced the publication of preclinical in vivo data in Drug Development Research highlighting BAER-101’s full suppression of seizure activity using the Genetic Absence Epilepsy Rats from Strasbourg (“GAERS”) model of absence epilepsy.